Results 91 to 100 of about 461 (138)

Mavacamten in Symptomatic Hypertrophic Cardiomyopathy: A Paradigm Shift or Revolution? [PDF]

JACC Asia
Hung CL, Liu YW, Wu YW.
europepmc   +1 more source

New Insights in the Diagnosis and Treatment of Atrial Fibrillation in Patients with Hypertrophic Obstructive Cardiomyopathy. [PDF]

J Clin Med
Angelescu CM, Iosifescu TA, Căldăraru CI, Dermengiu AD, Ioniţă OR, Moldovan H, Dorobanţu LF.   +6 more
europepmc   +1 more source

Cardiac myosin inhibitors - a cutting-edge solution for the management of hypertrophic cardiomyopathy: a narrative review. [PDF]

Ann Med Surg (Lond)
Younas A, Qadri M, Ijlal A, Khan T, Pirzada L, Kumari V, Mubbashir A, Singh PK, Sherwani MRK, Noor R, Nausheen F, Ahmad B, Rahim H, Akilimali A.   +13 more
europepmc   +1 more source

Cardiac myosin inhibitors for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Hasana U, Korpal M, Haider F, Umer M, Lwin NPT, Iqbal S, Kumar R, Ahsan M, Hassan E, Ullah W, Khalid S, Gupta A, Alsubari AMA, Ehsan M, Ahmad A.   +14 more
europepmc   +1 more source

Efficacy of pharmacological therapies in reducing outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis. [PDF]

Eur Heart J Cardiovasc Pharmacother
Awad K, Pereyra Pietri M, Farina JM, Pathangey G, Abbas MT, Scalia IG, Le Couteur D, Wilanksy S, Lester SJ, Ommen SR, Geske JB, Arsanjani R, Ayoub C.   +12 more
europepmc   +1 more source

Cardiac myosin inhibitors: a silver lining for an old disease. [PDF]

Open Heart
Yadav S, Agstam S, Singh S.
europepmc   +1 more source

2026 Expert Consensus Recommendations on Hypertrophic Cardiomyopathy: A Report of the Task Force of the Taiwan Society of Cardiology. [PDF]

Acta Cardiol Sin
Hung CL, Wu YW, Lai CH, Chen ML, Liang HY, Kuo L, Wang CL, Tseng H, Juang JJ, Liu YW, Tsai WC, Chang HY, Chang WT, Chen PS, Hsieh IC, Yu WC, Li YH.   +16 more
europepmc   +1 more source

The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review. [PDF]

Heart Fail Rev
Othman L, Koskina L, Huerta N, Rao SJ.
europepmc   +1 more source

CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy. [PDF]

Eur J Clin Pharmacol
Kasolo Y, Burford E, Obeidat M, Beaman GM, Monk T, Bastiaenen R, Newman WG, Cooper RM.   +7 more
europepmc   +1 more source